

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63

August 9, 2021

ISSUE No.
1630

IN THIS ISSUE

In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine.....p 121

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63 (Issue 1630)

August 9, 2021

Take CME Exams

IN BRIEF

Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine

On July 12, 2021, the FDA added a warning to the Fact Sheet for the Johnson & Johnson (Janssen) adenovirus-based COVID-19 vaccine about an increased risk of Guillain-Barré syndrome (GBS) following administration of the product.¹

The warning is based on 100 cases of GBS that were reported to the Vaccine Adverse Events Reporting System (VAERS) following administration of the Johnson & Johnson vaccine. Most of the cases occurred within 42 days of vaccination; 95 of the 100 persons who developed GBS required hospitalization, and 1 died. About 12.5 million doses of the Johnson & Johnson vaccine had been administered at the time the warning was issued.^{2,3}

According to the CDC, 3000-6000 cases of GBS are reported annually in the US. In many cases, GBS occurs following a viral or bacterial infection, including COVID-19.⁴ The syndrome has been reported following administration of other vaccines, including the Oxford-AstraZeneca adenovirus-based COVID-19 vaccine (not authorized for use in the US).⁵

Recipients of the Johnson & Johnson vaccine who develop weakness or tingling in the legs or arms that worsens or spreads or who have difficulty with walking, facial or ocular movement, bladder control, or bowel function should seek immediate medical attention. The Pfizer-BioNTech and Moderna mRNA-based COVID-19 vaccines have not been associated with GBS to date.² ■

4. S Abu-Rumeileh et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. *J Neurol* 2021; 268:1133.
5. CM Allen et al. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. *Ann Neurol* 2021 June 10 (epub).

1. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). July 8, 2021. Available at: <https://bit.ly/3e6KEaD>. Accessed July 15, 2021.
2. FDA News Release. Coronavirus (COVID-19) update: July 13, 2021. Available at: <https://bit.ly/3zg9NHt>. Accessed July 15, 2021.
3. Johnson & Johnson. Johnson & Johnson statement on COVID-19 vaccine (7/12). July 12, 2021. Available at: <https://bit.ly/3kmg6EY>. Accessed July 15, 2021.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, M.S., Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
 www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
 please e-mail your request to:
 permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:  

Copyright 2021. ISSN 1523-2859

